Mirikizumab  (Synonyms: LY­3074828)

Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with K_d values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease^[1][2].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Humanized

Mirikizumab (4.4 pM - 800 nM, 48 h) can completely neutralize IL-17A production induced by human and cynomolgus monkey IL-23 in mouse splenocytes, with IC₅₀ values of 82 pM and 120 pM for human and cynomolgus monkey IL-23, respectively^[2].
Mirikizumab (0.1 ng/mL - 1 μg/mL, 48 h) can completely inhibit IL-17 secretion induced by anti-CD3/anti-CD28 and IL-23 in two different human peripheral blood mononuclear cell (PBMC) preparations, with IC₅₀ values of 22 μg/mL and 29 μg/mL for these PBMC preparations, respectively^[2].
Mirikizumab (50 or 500 ng/mL, 48 h) does not affect IL-12-induced STAT4 phosphorylation in Kit225 and TALL-104 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Mirikizumab (7.5 mg/kg, i.p., administered at 9, 16, and 32 hours) exhibits anti-inflammatory activity in an acute systemic mouse model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1884201-71-1

Liquid

Colorless to light yellow

[Mirikizumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Immobilized Human IL-23 P19/IL23A Protein (mFc Tag) can bind Mirikizumab. The EC₅₀ for this effect is 4.802 ng/mL.

• [1]. Jefremow A, et al. Some are More Equal: Targeting IL 12 and 23 in IBD - A Clinical Perspective. Immunotargets Ther. 2020 Nov 26;9:289-297.

  [2]. Steere B, et al. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23. J Pharmacol Exp Ther. 2023 Nov;387(2):180-187. Steere B, Beidler C, Martin A, Bright S, Kikly K, Benschop RJ. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23. J Pharmacol Exp Ther. 2023 Nov;387(2):180-187.  [Content Brief]